Dapagliflozin: Discovery, Development, Safety and Pharmacovigilance

Explains the evolution of dapagliflozin from renal glucose-transport inhibition through pivotal cardiovascular, heart-failure and renal trials, authorisation expansions, metabolic emergencies, infection risks and EU regulatory oversight.

Take test

Dapagliflozin: Discovery, Development, Safety and Pharmacovigilance

Dapagliflozin is a selective inhibitor of the sodium–glucose cotransporter 2 (SGLT2), which mediates substantial glucose reabsorption in the renal proximal tubule. Although initially developed as an insulin-independent glucose-lowering medicine for type 2 diabetes, dapagliflozin subsequently established clinically useful effects in heart failure and chronic kidney disease, including among people without diabetes. Understanding that progression is essential for evaluating its benefit–risk balance: an adverse event, benefit or recommended precaution must be interpreted in the context of the treated disease, renal function, treatment regimen and authorised indication. [1–4]

The scientific subject here is the international nonproprietary name dapagliflozin. Forxiga identifies the EU reference product, containing dapagliflozin propanediol monohydrate; separate fixed combinations and regional brand names do not establish separate active-substance histories. This article follows discovery, evidence development, regulatory transitions and safety-system implications.

Scientific rationale and discovery

Renal glucose transport as a pharmacological target

Glucose filtered through the glomerulus is normally reclaimed in the proximal tubule. SGLT2 mediates much of the early tubular glucose uptake, working with the sodium gradient. Inhibiting this transporter increases urinary glucose excretion, modestly affects sodium handling and changes intrarenal physiology. This mechanism is independent of stimulating pancreatic insulin secretion, which initially made SGLT2 blockade attractive in type 2 diabetes. [1]

The concept drew on observations involving phlorizin, a naturally occurring inhibitor of renal glucose transport, but phlorizin was poorly suited to routine oral selective SGLT2 inhibition. Medicinal chemistry subsequently produced orally active selective inhibitors, including dapagliflozin, with a carbon-linked glucoside scaffold intended to improve metabolic stability. Development occurred in the Bristol Myers Squibb programme, subsequently partnered commercially with AstraZeneca. Assigning the original medicinal-chemistry work to AstraZeneca alone would conflate later commercial control with discovery. [5]

Why one mechanism supports three disease areas

Glucose lowering is the most obvious consequence in hyperglycaemia, but changes in sodium delivery, renal haemodynamics, extracellular fluid balance and other interconnected processes help explain interest in heart and kidney outcomes. The complete causal pathways behind every observed outcome remain under investigation. SGLT2 inhibition does not directly replace insulin, and its glucose-lowering efficacy falls as kidney filtration declines. Conversely, loss of glycaemic effect at lower eGFR does not automatically imply loss of heart-failure or chronic-kidney-disease benefit in populations where those outcomes have been studied. [1–4]

Authorisation and commercial development

In 2012, AstraZeneca and Bristol Myers Squibb announced a positive CHMP opinion for dapagliflozin in type 2 diabetes. The European Commission granted the Forxiga marketing authorisation on 11 November 2012. The EMA's current EPAR identifies AstraZeneca AB as marketing authorisation holder and specifies three broad EU areas of use: type 2 diabetes, symptomatic chronic heart failure in adults and chronic kidney disease in adults. The diabetes indication covers adults and children aged ten years and above, within the limitations of the authorised SmPC. [1,5]

The expansion from glycaemic management to cardiorenal indications followed dedicated randomised-outcome studies; it did not arise simply because diabetes trials recorded fewer cardiovascular events. The EMA lists its latest public product-information update as 12 March 2026. Product-specific dosing, restrictions and warnings should be read in that version and subsequent approved updates, not inferred from the initial 2012 licence.

For the commercial history, the original Bristol Myers Squibb–AstraZeneca diabetes alliance and AstraZeneca's subsequent acquisition of Bristol Myers Squibb's interests in the alliance provide relevant ownership context. Revenue of a product family or fixed combination must not automatically be assigned to dapagliflozin alone. [5]

Clinical development: from metabolic efficacy to outcomes

Type 2 diabetes and DECLARE–TIMI 58

Early phase III studies established glycaemic effects in type 2 diabetes under specified renal and treatment conditions. The large DECLARE–TIMI 58 cardiovascular-outcome trial then randomised 17,160 patients with type 2 diabetes and established atherosclerotic cardiovascular disease or multiple risk factors. Dapagliflozin satisfied the trial's prespecified noninferiority criterion for major adverse cardiovascular events (MACE) versus placebo. It did not establish superiority on MACE. The composite of cardiovascular death or hospitalisation for heart failure was reduced, principally through fewer heart-failure hospitalisations. These statements must remain distinct because a positive secondary cardiorenal pattern cannot turn a non-significant MACE-superiority result into a demonstrated effect. [2]

Heart failure across the ejection-fraction range

In DAPA-HF, patients with symptomatic heart failure and reduced ejection fraction were randomised to dapagliflozin or placebo in addition to background care; the study included participants with and without type 2 diabetes. The primary composite combined worsening heart failure and cardiovascular death. Its improvement supported the expansion beyond glycaemic treatment. [3]

DELIVER then evaluated 6,263 people with symptomatic heart failure and left ventricular ejection fraction greater than 40%. Over median follow-up of 2.3 years, worsening heart failure or cardiovascular death occurred in 16.4% of dapagliflozin recipients and 19.5% of placebo recipients (hazard ratio 0.82, 95% CI 0.73–0.92). The composite benefit does not mean the trial independently proved a significant reduction in each component: cardiovascular death alone had a confidence interval crossing unity. [4]

Chronic kidney disease and DAPA-CKD

DAPA-CKD studied patients with chronic kidney disease, with or without type 2 diabetes, and assessed sustained decline in estimated GFR, kidney failure and cardiovascular or renal death in a prespecified composite. Its findings supported the use of dapagliflozin to reduce kidney-disease progression in studied populations, extending the therapeutic story beyond diabetes. The published trial population, baseline albuminuria and renal function limits are essential when interpreting generalisability. [6]

Evidence Main population What it established What it did not establish
DECLARE–TIMI 58 Type 2 diabetes with cardiovascular disease or risk factors Cardiovascular safety noninferiority; lower HF hospitalisation-containing composite MACE superiority
DAPA-HF Symptomatic HFrEF Lower worsening-HF/CV-death composite Identical results in every HF phenotype
DELIVER HF with EF above 40% Lower worsening-HF/CV-death composite Significant mortality reduction from each component alone
DAPA-CKD Defined CKD population, with or without diabetes Lower kidney-progression-containing composite Evidence for every cause or severity of CKD

The progressive evidence base illustrates why indication-specific risk appraisal matters. A patient taking dapagliflozin for heart failure without diabetes may develop ketoacidosis under unusual physiological stress; the absence of diabetes should not cause clinical teams to exclude a serious metabolic event solely on the basis of indication.

Safety profile and special situations

Ketoacidosis, including near-normal glucose presentations

SGLT2 inhibitors may be associated with diabetic ketoacidosis, sometimes without markedly elevated blood glucose. Reduced caloric or carbohydrate intake, acute illness, dehydration, surgery, insulin deficiency and other metabolic stressors can contribute. Recognition should therefore use symptoms, acid–base findings and ketone measurements rather than assuming that glucose below conventional DKA thresholds rules out the diagnosis. The applicable SmPC describes interruption, evaluation and restarting precautions; these instructions must not be replaced by a generic fixed stopping interval. [1]

The distinction between the approved indication and the patient's underlying physiology is particularly relevant during intercurrent illness. PV assessment should capture indication, type of diabetes if any, recent insulin changes, fasting, surgery, dehydration, blood glucose, pH, bicarbonate, ketones, anion gap and treatment outcome. MedDRA coding should reflect the medically established diagnosis, not an invented classification based solely on urine ketones.

Genital infections, urinary infections and severe complications

Glucosuria changes the local environment and is associated with genital mycotic infections. Urinary-tract infections can also occur, with serious presentations requiring prompt evaluation. Rare but serious necrotising fasciitis of the perineum (Fournier's gangrene) is a class safety concern reflected in product information. A diagnosis of Fournier's gangrene should not be inferred from uncomplicated genital symptoms. Clinical case analysis should distinguish infection type, anatomic site, culture results, diabetes status, immunosuppression, intervention and outcome. [1]

Volume depletion and renal physiology

Osmotic diuresis and changes in salt handling can cause volume-related symptoms, hypotension or clinically significant dehydration, especially in susceptible patients or those receiving diuretics. Initial eGFR changes following initiation need interpretation against renal haemodynamics, baseline kidney function and other causes of acute deterioration. The demonstrated long-term renal benefits in trial populations do not rule out episodes of acute kidney injury during severe volume depletion or intercurrent disease. [1,6]

Hypoglycaemia, pregnancy and special populations

Dapagliflozin used without medicines that directly lower glucose through insulin secretion generally has a different hypoglycaemia profile from insulin or sulfonylureas. Concomitant insulin or insulin secretagogues can increase hypoglycaemia risk and may require adjustment following clinical assessment. In pregnancy and lactation, product information reflects restrictions associated with limited human data and developmental renal concerns; the current EU SmPC should be consulted for precise wording. Paediatric treatment is authorised for the relevant type 2 diabetes indication, not automatically for adult heart-failure or CKD indications. [1]

Pharmacovigilance implementation and governance

European marketing authorisation holders must meet applicable pharmacovigilance requirements under EU legislation and implementing rules. EMA GVP guidance describes operational expectations for individual-case management, signal evaluation, periodic benefit–risk assessment and quality systems. Recommended case-level clinical details below illustrate sound operational practice and are not new dapagliflozin-specific legal fields. [7]

Clinical evaluation and traceability

A clinically useful suspected-reaction report identifies the formulation, dose and dates; its actual therapeutic indication; background kidney function and disease; concurrent antidiabetic and diuretic medicines; intercurrent stressors; diagnostic evidence; management; and outcome. Assessment of DKA or genital infection must distinguish established reactions from diagnostic uncertainty. A report of a fall in eGFR needs baseline and serial values, illness and fluid status, and subsequent evolution. Duplicate detection matters when serious cases are sent independently by patients, hospitals and manufacturers.

Signal evaluation should compare the accumulated information against current labelled safety, exposure in different indications, clinical-trial denominators where available and emerging evidence. Seriousness, causality, expectedness, severity and preventability remain different concepts. The fact that a serious outcome occurred after medicine initiation is not itself proof of drug causation.

Illustrative inspection scenario

Consider a hypothetical set of ketoacidosis reports following perioperative fasting. An inspector evaluating PV effectiveness might examine whether original narratives and clinical laboratory evidence were retained, whether the possibility of relatively modest blood glucose was considered, whether suspected interactions and procedural circumstances were coded appropriately, and whether the cumulative review drove proportionate risk-minimisation actions. This is a hypothetical inspection scenario, not a published finding.

A second failure mode is transferring an old diabetes-only risk assessment to heart failure and CKD populations without reviewing underlying comorbidities and medicine combinations. Such an approach could miss new exposure contexts even when the adverse reaction itself is already listed.

Summary

Dapagliflozin demonstrates a major therapeutic shift from insulin-independent glucose lowering to outcome-driven treatment of chronic heart failure and kidney disease. DECLARE–TIMI 58, DAPA-HF, DELIVER and DAPA-CKD support different, complementary claims; their endpoints and study populations must not be merged. EU pharmacovigilance must similarly remain indication- and product-aware while recognising established hazards including ketoacidosis, genital infection, severe infection and volume depletion.

References

  1. European Medicines Agency. Forxiga EPAR and product information; authorised indications and 12 March 2026 product information update. https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga
  2. Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357. https://doi.org/10.1056/NEJMoa1812389
  3. McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
  4. Solomon SD, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. https://doi.org/10.1056/NEJMoa2206286
  5. AstraZeneca and Bristol Myers Squibb. Forxiga receives positive CHMP opinion in the EU, 20 April 2012. https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-receives-positive-CHMP-opinion-in-the-European-Union-for-the-treatment-of-type-2-diabetes-20042012.html
  6. Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. https://doi.org/10.1056/NEJMoa2024816
  7. European Medicines Agency. Good pharmacovigilance practices. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp

Regulatory Note

This reference distinguishes EU product authorisation and labelled safety from clinical-trial evidence, regulatory interpretation and illustrative good practice. Local language versions of current EU product information govern specific treatment decisions. Trial results do not automatically extend to unstudied populations or establish efficacy for other SGLT2 inhibitors.

Revision History

QPPV.com